Case studies with new excipients: Development, implementation and regulatory approval

Therapeutic Delivery

Volumn 2, Issue 7, 2011, Pages 949-956

  Koo, Otilia M Y ^a   Varia, Sailesh A ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CYCLODEXTRIN SULFOBUTYL ETHER; ESCITALOPRAM; EXCIPIENT; LEVO T; LEVOTHYROXINE; NIFEDIPINE; POLYOXYL 15 HYDROXYSTEARATE; PROSTAGLANDIN E2; SILICALCIFIED MICROCRYSTALLINE CELLULOSE; UNCLASSIFIED DRUG; VFENDBETA; VORICONAZOLE;

DATA BASE; DRUG FORMULATION; DRUG MARKETING; DRUG SAFETY; DRUG SOLUBILITY; DRUG STABILITY; EUROPE; FOOD AND DRUG ADMINISTRATION; JAPAN; MEDICAL LITERATURE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; UNITED STATES;

EID: 79953239836     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.11.62     Document Type: Review

References (22)

1. Koo OMY. Advances and examples of new excipients in novel drug-delivery systems. Presented at: Annual Meeting of the American Association of Pharmaceutical Scientists. New Orleans, LA, USA, 14-18 November 2010.
2. US Food and Drug Administration. Guidance for Industry: Nonclinical Studies for the Safety Evaluation of Pharmaceutical Excipients (2005).
3. Russell R. Synthetic excipients challenge all-natural organics. Pharm. Technol. 27, 38-50 (2004).
4. Moreton RC. Functionality and performance of excipients in a quality-by-design world, part IX: new excipients. Am. Pharm. Rev. 34-37 (2010).
5. Koo O. Application challenges and examples of new excipients in advanced drug delivery systems. Am. Pharm. Rev. 60-68 (2011).
6. Velagaleti R. Excipient innovation and regulatory acceptance for use in drug products - solubilizer solutol® HS 15 case study. Presented at: Annual Meeting of the American Association of Pharmaceutical Scientists. Los Angeles, CA, USA, November 2009.
7. United States Pharmacopeia. Polyoxyl 15 hydroxystearate. Pharmacopeial Forum 35(1), 128 (2009).
8. Bley H, Fussnegger B, Bodmeier R. Characterization and stability of solid dispersions based on PEG/polymer blends. Intl J. Pharmaceutics 390, 165-173 (2010).
9. Moreton RC. IPEC - Americas new excipient evaluation procedure. Presented at: Annual Meeting of the American Association of Pharmaceutical Scientists. New Orleans, LA, USA, 14-18 November 2010.
10. Brewster ME, Loftsson T. Cyclodextrins as pharmaceutical solubilizers. Adv. Drug Deliv. Rev. 59, 645-666 (2007). (Pubitemid 47299263)
11. Stella VJ, Rao VM, Zannou EA, Zia V. Mechanisms of drug release from cyclodextrin complexes. Adv. Drug Deliv. Rev. 36, 3-16 (1999). (Pubitemid 29074473)
12. Szejtli J. Cyclodextrin complexed generic drugs are generally not bio-equivalent with the reference products: therefore the increase in number of marketed drug cyclodextrin formulations is so slow. J. Inclusion Phenomena Macrocyclic Chem. 52, 1-11 (2005). (Pubitemid 40897908)
13. Szente L, Szejtli J. Highly soluble cyclodextrin derivatives: chemistry, properties, and trends in development. Adv. Drug Del. Rev. 36, 17-28 (1999). (Pubitemid 29074474)
14. Block LH. Co-processed excipients. Pharmacopeial Forum 35(4), 1026-1028 (2009).
15. Tobyn MJ, McCarthy GP, Staniforth JN, Edge S. Physicochemical comparison between microcrystalline cellulose and silicified microcrystalline cellulose. Int. J. Pharm. 169, 183-194 (1998). (Pubitemid 28345254)
16. Nurnberg E, Wunderlich J. Coating of cellulose products with highly dispersed silicic acid: investigations on the improvement of tabletting properties demonstrated in low dose tablets. Pharm. Ind. 57(3), 252-256 (1995).
17. Edge S, Steele DF, Chen A, Tobyn MJ, Staniforth JN. The mechanical properties of compacts of microcrystalline cellulose and silicified microcrystalline cellulose. Int. J. Pharm. 200, 67-72 (2000). (Pubitemid 30177251)
18. Aljaberi A, Chatterji A, Shah NH, Sandhu HK. Functional performance of silicified microcyrtsalline cellulose versus microcrystalline cellulose: a case study. Drug Dev. Ind. Pharm. 35(9), 1066-1071 (2009).
19. Heng PWS, Koo OMY. A study of the effects of the physical characteristics of microcrystalline cellulose on performance in extrusion spheronization. Pharm. Res. 18(4), 480-487 (2001). (Pubitemid 32592580)
20. Chaubal MV. Excipient update: silicified microcrystalline cellulose. Drug Development Delivery 3(1), 30-35 (2003).
21. Zeleznik JA, Renak J. High functionality excipients (HFE) - Prosolv® SMCC as an effective strategy for generic drug formulation. Business Briefing: Pharmagenerics 1-4 (2004).
22. United States Pharmacopeia. Silicified microcrystallaine cellulose. Pharmacopeial Forum 34(5), 1218 (2008).